RE: Avacta11 May 2021 00:20
@upomega: with the best will in the world CD4 is not going anywhere until Covid is a distant memory, Food tech could take off but relying on china is always a risky business, they show little regards to patents and copyrights, at best the non-covid business supports an SP of 40-50p. Like it of not the fate of this company is hanging on the covid returns, and the HMG contract if we only get to phase 1, just isn't going to cut it £50M over 2 years with a margin of 18% is £4.5M profit a year, transformational when you consider it against a previous loss, but nothing to support the current mcap.
They have to sell the Visitect antigen in large numbers to make any traction, or obviously the UK pandemic roadmap falls apart and we do secure large production orders from the government.
This is purely my speculation, Visitect Antigen or bust.